Spyre Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Okay. We'll continue with the next session. I'm Paul Choi, and I cover the mid-cap biotech sector here at the firm. It's my pleasure to have Spyre Therapeutics here and Cameron to my left. Maybe what we'll do is kick it off with Cameron talking about maybe what the company's strategic priorities are for the remainder of the year and going into 2027.
Yeah, good. So as a brief background, Spyre is a company that's aiming to improve the standard of care across the range of autoimmune diseases. Our initial focus was inflammatory bowel disease, where we're working on three validated targets, α4β7, TL1A and IL-23 and developing them not only as monotherapies, but in advanced combination therapies as well, where we think we have some of the most interesting co-formulated long-acting combinations of these agents. Outside of IBD, we're also interested in exploring the potential of TL1A as a pipeline in a product candidate in a range, we're
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
